<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245839</url>
  </required_header>
  <id_info>
    <org_study_id>JCAR017-FOL-001</org_study_id>
    <secondary_id>U1111-1244-9768</secondary_id>
    <secondary_id>2019-004081-18</secondary_id>
    <nct_id>NCT04245839</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)</brief_title>
  <acronym>TRANSCEND FL</acronym>
  <official_title>A Phase 2, Open-label, Single Arm, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 (Lisocabtagene Maraleucel) in Adult Subjects With High-risk, Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate&#xD;
      efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.&#xD;
&#xD;
      The study will be conducted in compliance with the International Council on Harmonisation&#xD;
      (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good&#xD;
      Clinical Practice (GCP) and applicable regulatory requirements.&#xD;
&#xD;
      This study is divided into three periods:&#xD;
&#xD;
        -  Pretreatment, which consists of screening assessments, leukapheresis and the&#xD;
           Pretreatment evaluation;&#xD;
&#xD;
        -  Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and&#xD;
           continues through JCAR017 administration at Day 1 with follow-up through Day 29;&#xD;
&#xD;
        -  Posttreatment, which includes follow-up assessments for disease status and safety for 2&#xD;
           years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">April 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Is defined as the percentage of participants achieving either a partial response (PR) or complete response (CR) at any time up to 24 months after JCAR017 treatment as assessed by PET-CT and/or CT using &quot;The Lugano classification&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR) as assessed but PET-CT and/or CT using &quot;The Lugano Classification&quot;</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Is defined as the percentage of subjects achieving a CR at any time up to 24 months after JCAR017 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) if Best Overall Response (BOR) is CR, as assessed by PET-CT and/or CT using &quot;The Lugano Classification&quot;</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>is defined for subjects with a BOR of CR as the time from first response (CR or PR) to disease progression or death from any cause up to 24 months after JCAR017 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as assessed by PET-CT and/or CT using &quot;The Lugano Classification&quot;</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>is defined as the time from first response (CR or PR) to disease progression or death from any cause, whichever occurs first up to 24 months after JCAR017 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as assessed by PET-CT and/or CT using &quot;The Lugano Classification&quot;</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>is defined as the time from start of JCAR017 to disease progression or death from any cause, whichever occurs first up to 24 months after JCAR017 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>is defined as the time from start of JCAR017 to time of death due to any cause up to 24 months after JCAR017 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time to maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>is questionnaire that will be used as a measure of health-related quality of life.&#xD;
The EORTC QLQ-C30 is composed of both multi-item scales and single item measures. These include five functional scales (physical, role, emotional, cognitive and social), three symptom scales (fatigue, nausea/vomiting, and pain), a global health status/health-related quality of life (HRQoL) scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality Assessment of Cancer Therapy Lymphoma Subscale (FACT-LymS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>is a 15-item lymphoma-specific additional concerns subscale. This subscale addresses symptoms and functional limitations are important to lymphoma patients. The FACT-LymS items are scored on a 0 (&quot;Not at all&quot;) to 4 (&quot;Very much&quot;) response scale. Items are aggregated to a single score on a 0-60 scale. High scores indicate lower symptom burden.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Administration of JCAR017</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents.&#xD;
JCAR017 will be infused on Day 1 at a dose of 100 Ã— 10^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine</description>
    <arm_group_label>Administration of JCAR017</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide</description>
    <arm_group_label>Administration of JCAR017</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JCAR017</intervention_name>
    <description>JCAR017</description>
    <arm_group_label>Administration of JCAR017</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone&#xD;
             lymphoma (MZL) histologically confirmed within 6 months of screening, as assessed by&#xD;
             local pathology&#xD;
&#xD;
          2. Patients should have received at least one prior therapy that includes anti-CD20 and&#xD;
             alkylating agent&#xD;
&#xD;
          3. Follicular lymphoma patients: Received at least one prior line of systemic therapy.&#xD;
             Patients that received one prior line of systemic therapy are eligible if they present&#xD;
             with high risk features. Patients that received two or more prior lines of systemic&#xD;
             therapy are eligible, assuming one of the prior lines includes anti-CD20 and&#xD;
             alkylating agent (as listed in criterion 2)&#xD;
&#xD;
          4. Marginal zone lymphoma patients: Received two or more prior lines of systemic therapy,&#xD;
             assuming one of the prior lines includes anti-CD20 and alkylating agent (as listed in&#xD;
             criterion 2) or relapsed after hematopoietic stem cell transplant&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
          7. Adequate vascular access for leukapheresis procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL, or of&#xD;
             transformed FL&#xD;
&#xD;
          2. WHO subclassification of duodenal-type FL&#xD;
&#xD;
          3. Central nervous system-only involvement by malignancy (subjects with secondary central&#xD;
             nervous system (CNS) involvement are allowed on study)&#xD;
&#xD;
          4. History of another primary malignancy that has not been in remission for at least 2&#xD;
             years, with the exception of non-invasive malignancies&#xD;
&#xD;
          5. Prior CAR T-cell or other genetically-modified cell therapy&#xD;
&#xD;
          6. History of or active human immunodeficiency virus (HIV)&#xD;
&#xD;
          7. Active hepatitis B or active hepatitis C&#xD;
&#xD;
          8. Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate&#xD;
             antibiotics or other treatment&#xD;
&#xD;
          9. Active autoimmune disease requiring immunosuppressive therapy&#xD;
&#xD;
         10. Presence of acute or chronic graft-versus-host=disease&#xD;
&#xD;
         11. History of significant cardiovascular disease&#xD;
&#xD;
         12. History or presence of clinically relevant central nervous system pathology&#xD;
&#xD;
         13. Allogenic-hematopoietic stem cell transplant (Allo-HSCT) within 90 days of&#xD;
             leukapheresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thalia Farazi, M.D./Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Medical Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Medical Centre-Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annabel Liu</last_name>
      <phone>310-206-3137</phone>
      <email>agliu@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Wax</last_name>
      <phone>720-848-9384</phone>
      <email>rachel.wax@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Health - Smilow Cancer Hospita</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Dormal, RN BSN</last_name>
      <phone>203-833-2701</phone>
      <email>Alexandra.dormal@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pavan Anant</last_name>
      <email>pavan.anant@yale.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists - Arlington Heights</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Lynn</last_name>
      <phone>847-827-9060</phone>
      <email>lisbeth.lynn@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Dana-Farber Cancer Institute (The Jon and JoAnn Hagler Center for Lymphoma)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Arnason,, MD</last_name>
      <phone>617-667-9920</phone>
      <email>jarnason@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pavania Elavalakanar</last_name>
      <phone>617-667-1903</phone>
      <email>pelavala@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Lau</last_name>
      <phone>646-608-2091</phone>
      <email>cart@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>M. Lia Palomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Cancer Specialists Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Skarbnik, MD</last_name>
      <phone>704-316-3297</phone>
      <email>azskarbnik@novanthealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Kunal Shah</last_name>
      <phone>704-384-8823</phone>
      <email>kashah@novanthealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>taussigresearch@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center - Earle A. Chiles Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine - Abramson Cancer Center University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael McNicholas, RN</last_name>
      <email>Michael.McNicholas@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tanya Latorre, RN</last_name>
      <email>Tanya.Latorre@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Avera Research Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Brandt, RN</last_name>
      <phone>888-422-1410</phone>
      <email>hematologyresearch@avera.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Jackson, RN</last_name>
      <phone>888-422-1410</phone>
      <email>hematologyresearch@avera.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ly Dsouza, PA-C</last_name>
      <phone>713-745-8614</phone>
      <email>ldsouza@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Jaeger</last_name>
      <phone>+43114040044090</phone>
      <email>ulrich.jaeger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Mercedes Litzenberger</last_name>
      <phone>+4314040044100</phone>
      <email>mercedes.litzenberger@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve - Rosemont</name>
      <address>
        <city>Quebec</city>
        <state>Montreal</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Ontario</city>
        <state>Toronto</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'Ile-de-Montreal - Installation Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Cormier, MD</last_name>
      <email>olivier.cormier.cemtl@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde Prunier</last_name>
      <email>mathilde.prunier.cemtl@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle Fleury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU-Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny Joly</last_name>
      <phone>+33320444022</phone>
      <email>fanny.joly@chru.lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Nung</last_name>
      <phone>+33320444022</phone>
      <email>alexandre.nung@chru-lille.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - HÃ´pital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecile Popko</last_name>
      <phone>+33467338366</phone>
      <email>c-popko@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marguerite Lepicard</last_name>
      <phone>+33467335379</phone>
      <email>m-lepicard@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universitat Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Gahl</last_name>
      <phone>+497315004593</phone>
      <email>peter.gahl@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariangela Saggese, Pharm D.</last_name>
      <phone>+39 0 81 5903 2014</phone>
      <email>m.saggese@istitutotumori.na.it</email>
    </contact>
    <contact_backup>
      <last_name>Gianpaolo Marcacci, MD</last_name>
      <phone>+39 0 81 5903 204</phone>
      <email>g.marcacci@istitutotumori.na.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Minato-ku</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi, Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitario de Salamanca - Hospital Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Prieto Garcia</last_name>
      <phone>0034 92329 1100</phone>
      <phone_ext>55974</phone_ext>
      <email>lprietog@saludcastillayleon.es</email>
    </contact>
    <contact_backup>
      <last_name>Eva Diez Baeza</last_name>
      <phone>0034 92391100</phone>
      <phone_ext>55974</phone_ext>
      <email>ediez.ibsal@saludcastillayleon.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Luis Reguera Ortega</last_name>
      <phone>+34955013277</phone>
      <email>juanl.reguera.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Estefania Menendez</last_name>
      <phone>+34955013277</phone>
      <email>estefania.menendez@juntadeandalucia.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S- 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leigh Wood</last_name>
      <phone>0790839901</phone>
      <email>leigh.wood@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Clemency Every-Clayton</last_name>
      <phone>7779560148</phone>
      <email>clemency.every-clayton@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Withington</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell Non-Hodgkin Lymphoma (NHL)</keyword>
  <keyword>JCAR017</keyword>
  <keyword>Relapsed or Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

